WO2003013455A2 - Formulations cosmetiques et dermatologiques photoprotectrices contenant des derives de benzotriazole et des particules de latex - Google Patents

Formulations cosmetiques et dermatologiques photoprotectrices contenant des derives de benzotriazole et des particules de latex Download PDF

Info

Publication number
WO2003013455A2
WO2003013455A2 PCT/EP2002/008582 EP0208582W WO03013455A2 WO 2003013455 A2 WO2003013455 A2 WO 2003013455A2 EP 0208582 W EP0208582 W EP 0208582W WO 03013455 A2 WO03013455 A2 WO 03013455A2
Authority
WO
WIPO (PCT)
Prior art keywords
acid
preparations
red
derivatives
contain
Prior art date
Application number
PCT/EP2002/008582
Other languages
German (de)
English (en)
Other versions
WO2003013455A3 (fr
Inventor
Jens Schulz
Anja Göppel
Wiebke Grundt
Original Assignee
Beiersdorf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf Ag filed Critical Beiersdorf Ag
Priority to EP02762421A priority Critical patent/EP1416912A2/fr
Publication of WO2003013455A2 publication Critical patent/WO2003013455A2/fr
Publication of WO2003013455A3 publication Critical patent/WO2003013455A3/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241Containing particulates characterized by their shape and/or structure
    • A61K8/0279Porous; Hollow
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4966Triazines or their condensed derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8147Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41Particular ingredients further characterized by their size
    • A61K2800/412Microsized, i.e. having sizes between 0.1 and 100 microns
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60Particulates further characterized by their structure or composition
    • A61K2800/65Characterized by the composition of the particulate/core
    • A61K2800/654The particulate/core comprising macromolecular material

Definitions

  • the present invention relates to cosmetic and dermatological light protection preparations, in particular it relates to sand-repellent cosmetic and dermatological light protection preparations.
  • the damaging effect of the ultraviolet part of solar radiation on the skin is generally known.
  • the rays have different effects on the skin organ:
  • the so-called UV-C radiation with a wavelength that is less than 290 nm is absorbed by the ozone layer in the earth's atmosphere and therefore has no physiological significance.
  • rays in the range between 290 nm and 320 nm, the so-called UV-B range cause an erythema, a simple sunburn or even more or less severe burns.
  • the narrower range around 308 nm is given as a maximum of the erythema effectiveness of sunlight.
  • Numerous compounds are known for protection against UV-B radiation, which are, for example, derivatives of 3-benzylidene camphor, 4-aminobenzoic acid, cinnamic acid, salicylic acid, benzophenone and s-triazine.
  • UV-A radiation is far more dangerous than UV-B radiation in terms of triggering photodynamic, especially phototoxic reactions and chronic changes in the skin.
  • the damaging influence of UV-B radiation can also be intensified by UV-A radiation.
  • UV-A radiation About 90% of the ultraviolet radiation reaching the earth consists of UV-A rays. While UV-B radiation varies greatly depending on numerous factors (e.g. time of year and time of day or latitude), UV-A radiation remains relatively constant day by day, irrespective of the time of year or day or geographical factors. At the same time, the major part of UV-A radiation penetrates the living epidermis, while around 70% of UV-B rays are retained by the horny layer.
  • aftersun or apres-soleil preparations are intended to cool the skin after sunbathing and to improve its moisturizing ability, whereby the imparting of the cooling effect plays a central role.
  • the state of the art lacks products that protect the skin from drying out during UV radiation and provide sufficient care.
  • Another disadvantage of the prior art is that conventional light protection formulations leave a mostly sticky film on the skin. This has e.g. B. when using such products on a sandy beach, the result is that the sand sticks to the body, which is perceived by the user as unpleasant and in the worst case can lead to the sunscreen being used too little or not at all. Since there is usually a more or less strong wind at the sea, this disadvantage usually occurs even when the body does not come into direct contact with the sand - for example when sunbathing on a deck chair - because the sand dust whirling around in the wind also occurs adheres to the creamed areas of the skin.
  • a further object of the present invention was therefore to find light protection formulations which, after use, do not leave any sand stuck to the creamy skin, which are therefore to be described as sand-repellent.
  • the preparations can preferably contain, in addition to one or more oil phases, one or more water phases and, for example, in the form of W / O, O / W, W / O / W or O / W / O emulsions .
  • Such formulations may preferably also be a microemulsion, a solid emulsion (i.e. an emulsion stabilized by solids, e.g. a Pickering emulsion), a sprayable emulsion or a hydrodispersion.
  • the emulsions according to the invention are preferably O / W emulsions.
  • the emulsions according to the invention are extremely satisfactory preparations, which are not limited to a restricted selection of raw materials. Accordingly, they are particularly suitable to serve as the basis for forms of preparation with a variety of uses.
  • the preparations according to the invention show very good sensory and cosmetic properties, such as, for example, the spreadability on the skin or the ability to be absorbed into the skin, and are furthermore distinguished by very good light protection effectiveness and, at the same time, excellent skin care data.
  • the invention therefore also relates to cosmetic or dermatological preparations which have a light protection effect, characterized in that they contain synergistic combinations of (a) at least one benzotriazole derivative and
  • UV protective power means both the protective power against UV-A radiation and against UV-B radiation.
  • a measure of the UV protection power in the sense of the present invention is, for example, the sun protection factor (SPF or SPF) or also IPD values and the like.
  • the sun protection factor indicates the prolongation of sun exposure, which is made possible by using the sunscreen. It is the quotient of erythema threshold time with sunscreen and erythema threshold time without sunscreen.
  • the IPD method (IPD ⁇ immediate pigment darkening) is usually used to test UV-A protection. Similar to the determination of the light protection factor, a value is determined which indicates how much longer the skin protected with the light protection agent can be irradiated with UV-A radiation until the same pigmentation occurs as for the unprotected skin.
  • the cosmetic and dermatological preparations in the sense of the present invention do not leave a greasy or sticky impression on the skin, are excellently compatible with the skin and are also surprisingly distinguished by the fact that they are sand-repellent.
  • the invention therefore also relates to cosmetic or dermatological light protection preparations, characterized in that they
  • (b) contain at least one type of latex particle which has an average particle size of 100 to 400 nm.
  • Latex particles with an average particle size of 150 to 375 nm, in particular from 190 to 350 nm, are advantageous in the sense of the present invention.
  • latex particles which have a cavity in their interior which, for example, is filled with air. It is particularly advantageous in the sense of the present invention if this cavity is as large as possible, insofar as the manufacturing conditions and the stability of the particles allow.
  • the latex particles according to the invention preferably contain a cavity of 0.1% to 50%, in particular 5% to 50%, in each case based on the volume of the particles.
  • Latex particles which are advantageous according to the invention consist of several layers and contain at least one inner polymer layer (“core polymer”) and at least one outer polymer layer (“shell polymer”).
  • core polymer an inner polymer layer
  • shell polymer an outer polymer layer
  • the core and shell polymer can be produced in a common or in successive polymerization steps.
  • the latex particles according to the invention are produced with the aid of customary polymerisation reactions, for example with the aid of sequential emulsion polymerisation.
  • customary polymerisation reactions for example with the aid of sequential emulsion polymerisation.
  • B. The in U.S. Patents 4,427,836; 4,469,825; 4,594,363; 4,677,003; 4,920,160 and 4,970,241. Further advantageous polymerization processes are further described in the following patent applications or documents: EP-A-267 726, EP-A-331 421 and US 4,910,229 and US 5,157,084.
  • Advantageous monomers which can be used, for example, in the course of an emulsion polymerization to produce the shell polymer contain one or more nonionic, ethylenic, unsaturated monomers, in particular one or more monoethylenic, unsaturated monomers which carry at least one carboxylic acid group.
  • the monomers from which the shell polymer is produced are advantageously chosen so that the shell polymer has a glass transition temperature in at least one layer which is high enough to support or maintain the cavity in the latex particle.
  • Advantageous monomers which can be used, for example, in the context of an emulsion polymerization to produce the core polymer, contain one or more monoethylenic, unsaturated monomers which carry at least one carboxylic acid group.
  • the core polymer advantageously contains at least 5% by weight of one or more monoethylenic, unsaturated monomers which carry at least one carboxylic acid group, based on the total weight of the monomers of the core polymer.
  • the core polymer can be obtained, for example, by emulsion homopolymerization of the monomers mentioned or by copolymerization of two or more such monomers.
  • Particularly advantageous core polymers can be obtained by copolymerizing a monoethylenic, unsaturated monomer with one or more non-ionic, ethylenic, unsaturated monomers.
  • Advantageous polyethylenic, unsaturated monomers for the purposes of the present invention which (individually or in mixtures) are present in core and / or shell polymer with a content of 0.1 to 20% by weight, preferably 3 to 20% by weight can include, for example, ethylene glycol di (meth) acrylate, allyl (meth) acrylate, 1,3-butanediol i (meth) acrylate, diethylene glycol di (meth) acrylate, trimethylolpropane tri (meth) acrylate or divinylbenzene.
  • the core and / or shell polymer can also contain 0.1 to 60% by weight of butadiene, in each case based on the total weight of the monomers.
  • Advantageous monoethylenic, unsaturated monomers which carry at least one carboxylic acid group are, for the purposes of the present invention, for.
  • acrylic acid and methacrylic acid acryloxypropionic acid, (meth) acryloxypropionic acid, itaconic acid, aconitic acid, maleic acid or anhydride, fumaric acid, crotonic acid, monomethyl maleate, monomethyl fumarate and / or monomethyl itaconate.
  • Acrylic acid and methacrylic acid are particularly preferred.
  • Suitable non-ionic, ethylenic, unsaturated monomers for the purposes of the present invention are, for. B. styrene, vinyl toloule, ethylene, vinyl acetate, vinyl chloride, vinylidene chloride, acrylonitrile, (meth) acrylamide, d - C 20 - alkyl or C 3 - C 20 - alkenyl esters of (meth) acrylic acid, such as methyl (meth) acrylate, ethyl (meth) acrylate, butyl (meth) acrylate, 2-ethylhexyl (meth) acrylate, benzyl (meth) acrylate, lauryl (meth) acrylate, oleyl (meth) acrylate, palmityl (meth) acrylate, and / or stearyl (meth) acrylate, in which the expression “(meth) acrylate” is to be understood generically for both terms “methacrylate
  • Latex particles which are advantageous according to the invention are those described in the following documents: US Pat. No. 5,663,213 and EP 0 761 201.
  • Latex particles are those which are formed from water and styrene / acrylate copolymers and, for. B. are available under the trade name "Alliance SunSphere” from Rohm & Haas. Commercial products of this type generally have an active content of 25 to 27% by weight.
  • active use concentration or “active content” in the sense of the present invention: B. in the form of a 50% solution (for example, because it is only available in this form on the market), then - at an application concentration of this "raw material solution” of 8.0 wt .-% - only one in the recipe "Active content” of 4.0 wt .-%, based on the total weight of the preparation, realized.
  • the total amount of one or more latex particles according to the invention in the finished cosmetic or dermatological preparations is advantageously in the range from 0.1 to 10.0% by weight, preferably 0.5 to 6.0% by weight. % selected, based on the total weight of the preparations.
  • a particularly advantageous benzotriazole derivative is 2,2'-methylene-bis- (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) phenol) [INCI: bisoctyltriazole], which is characterized by the chemical structural formula
  • B. is available under the trade name Tinosorb® M from CIBA-Chemical GmbH.
  • Another advantageous benzotriazole derivative for the purposes of the present invention is 2- (2H-benzotriazol-2-yl) -4-methyl-6- [2-methyl-3- [1, 3,3,3-tetramethyl-1 - [( trimethylsilyl) oxy] disiloxanyl] propyl] phenol (CAS No .: 155633-54-8) with the INCI name Drometrizole Trisiloxane, which is characterized by the chemical structural formula
  • the UV filter substance (s) according to the invention is / are advantageously incorporated into the water phase - particularly at a pH of more than 4.5 - of the cosmetic or dermatological formulations.
  • the cosmetic or dermatological light protection formulations according to the invention can be composed as usual and the cosmetic or dermatological Sun protection, also used for the treatment, care and cleaning of the skin and / or hair and as a make-up product in decorative cosmetics.
  • the cosmetic and dermatological preparations are applied to the skin and / or the hair in a sufficient amount in the manner customary for cosmetics.
  • the cosmetic and dermatological preparations according to the invention can contain cosmetic auxiliaries, such as are usually used in such preparations, for.
  • cosmetic auxiliaries such as are usually used in such preparations, for.
  • preservatives preservation aids, bactericides, perfumes, anti-foaming substances, dyes, pigments that have a coloring effect, thickeners, moisturizing and / or moisturizing substances, fillers that improve the skin feel, fats, oils, waxes or other common Components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • Advantageous preservatives for the purposes of the present invention are, for example, formaldehyde releasers (such as, for example, DMDM hydantoin), iodopropyl butyl carbamates (for example those available under the trade names Koncyl-L, Koncyl-S and Konkaben LMB from Lonza), parabens, Phenoxyethanol, ethanol, benzoic acid and the like.
  • the preservation system usually also advantageously comprises preservation aids, such as, for example, octoxyglycerol, glycine soya, etc.
  • compositions are also obtained if antioxidants are used as additives or active ingredients.
  • the preparations advantageously contain one or more antioxidants. All of the antioxidants suitable or customary for cosmetic and / or dermatological applications can be used as inexpensive, but nevertheless optional, antioxidants.
  • the antioxidants are advantageously selected from the group consisting of amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-Camosin, L-Camosin and their derivatives (e.g. anserine), carotenoids, carotenes (e.g. ⁇ -carotene, ß-carotene, lycopene) and their derivatives, lipoic acid and their derivatives (e.g.
  • amino acids e.g. glycine, histidine, tyrosine, tryptophan
  • imidazoles e.g. urocanic acid
  • peptides such as D, L-carnosine, D-Camosin, L-Camosin and their derivatives (e.g. anserine)
  • carotenoids
  • thiols e.g. thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl -, ⁇ -linoleyl, cholesteryl and glyceryl esters
  • salts dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g.
  • buthioninsulfoximines Homocysteine sulfoximine, buthionine sulfones, penta-, hexa-, heptathionine sulfoximine) in very low tolerable doses (e.g. pmol to ⁇ mol / kg), also (metal) chelators (e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, Lactoferrin), ⁇ -hydroxy acids (e.g.
  • citric acid lactic acid, malic acid
  • humi Acid bile acid
  • bile extracts bilirubin
  • biliverdin biliverdin
  • EDTA EGTA and their derivatives
  • unsaturated fatty acids and their derivatives e.g. B. ⁇ -linolenic acid, linoleic acid, oleic acid
  • folic acid and its derivatives ubiquinone and ubiquinol and their derivatives
  • vitamin C and derivatives e.g. ascorbyl palmitate, Mg - ascorbyl phosphate, ascorbyl acetate
  • tocopherols and derivatives e.g.
  • Vitamin E acetate
  • vitamin A and derivatives vitamin A palmitate
  • water-soluble antioxidants such as vitamins, e.g. B. ascorbic acid and its derivatives.
  • compositions according to the invention are very good vehicles for cosmetic or dermatological active ingredients in the skin, preferred active ingredients being antioxidants which can protect the skin against oxidative stress.
  • preferred active ingredients are vitamin E and its derivatives and vitamin A and its derivatives.
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 to 20% by weight, in particular 0.1 to 10% by weight, based on the total weight the preparation.
  • vitamin E and / or its derivatives represent the antioxidant (s)
  • vitamin A or vitamin A derivatives or carotenes or their derivatives represent the antioxidant or antioxidants, it is advantageous to add their respective concentrations in the range from 0.001 to 10% by weight, based on the total weight of the formulation choose.
  • the active ingredients can also be selected very advantageously from the group of lipophilic active ingredients, in particular from the following group:
  • B. evening primrose oil, borage oil or currant seed oil fish oils, cod liver oil but also ceramide
  • the active substances from the group of refatting substances, for example purcellin oil, Eucerit and Neocerit.
  • the active ingredient (s) are particularly advantageously selected from the group of NO synthase inhibitors, in particular if the preparations according to the invention for the treatment and prophylaxis of the symptoms of intrinsic and / or extrinsic skin aging and for the treatment and prophylaxis of the harmful effects of ultra- to serve violet radiation to the skin.
  • the preferred NO synthase inhibitor is nitroarginine.
  • the active ingredient (s) are also advantageously selected from the group comprising catechins and bile esters of catechins and aqueous or organic extracts from plants or parts of plants which contain catechins or bile esters of catechins, such as, for example, the leaves of Plant family Theaceae, especially the species Camellia sinensis (green tea).
  • catechins and bile esters of catechins and aqueous or organic extracts from plants or parts of plants which contain catechins or bile esters of catechins, such as, for example, the leaves of Plant family Theaceae, especially the species Camellia sinensis (green tea).
  • Their typical ingredients such as polyphenols or catechins, caffeine, vitamins, sugar, minerals, amino acids, lipids are particularly advantageous.
  • Catechins are a group of compounds which are to be regarded as hydrogenated flavones or anthocyanidins and derivatives of "catechins” (catechol, 3,3 ', 4', 5,7-flavanpentaol, 2- (3,4- Dihydroxyphenyl) -chroman-3,5,7-triol)
  • Catatechin ((2R, 3R) -3,3 ', 4', 5,7-flavanpentaol) is also an advantageous active substance in the sense of the present invention.
  • plant extracts containing catechins in particular extracts of green tea, such as. B. extracts from leaves of the plants of the species Camellia spec, especially the teas Camellia sinenis, C. assamica, C. talien- sis or C. irrawadiensis and crosses of these with, for example, Camellia japonica.
  • Preferred active ingredients are also polyphenols or catechins from the group (-) - catechol, (+) - catechin, (-) - catechin gallate, (-) - gallocatechin gallate, (+) - epicatechin, (-) - epicatechin , (-) - epicatechin gallate, (-) - epigallocatechin, (-) - epigallocatechin gallate.
  • Flavon and its derivatives are advantageous active substances in the sense of the present invention. They are characterized by the following basic structure (substitution positions specified):
  • flavones usually occur in glycosidated form.
  • the flavonoids are preferably chosen from the group of substances of the generic structural formula
  • Z, to Z 7 are selected independently of one another from the group H, OH, alkoxy and hydroxyalkoxy, where the alkoxy or hydroxyalkoxy groups can be branched and unbranched and can have 1 to 18 C atoms, and wherein Gly is selected from the group of mono- and oligoglycoside residues.
  • the flavonoids can also be advantageously selected from the group of substances of the generic structural formula
  • Z to Z 6 are independently selected from the group H, OH, alkoxy and hydroxyalkoxy, where the alkoxy or hydroxyalkoxy groups can be branched and unbranched and can have 1 to 18 carbon atoms, and wherein Gly is selected from the group Group of the mono- and oligoglycoside residues.
  • Such structures can preferably be selected from the group of substances of the generic structural formula
  • Glyi, Gly 2 and Gly 3 independently of one another represent monoglycoside residues or. Gly 2 or Gly 3 can also represent, individually or together, saturations by hydrogen atoms.
  • Glyi, Gly 2 and Gly 3 are preferably selected independently of one another from the group of the hexosyl radicals, in particular the rhamnosyl radicals and glucosyl radicals.
  • hexosyl radicals for example allosyl, altrosyl, galactosyl, gulosyl, idosyl, mannosyl and talosyl, may also be used advantageously. It can also be advantageous according to the invention to use pentosyl residues.
  • Z ⁇ to Z 5 are advantageously selected independently of one another from the group H, OH, methoxy, ethoxy and 2-hydroxyethoxy, and the flavone glycosides have the structure
  • Glyi, Gly 2 and Gly 3 independently of one another represent monoglycoside residues or. Gly 2 or Gly 3 can also represent, individually or together, saturations by hydrogen atoms.
  • Gly ⁇ Gly 2 and Gly 3 are preferably selected independently of one another from the group of the hexosyl residues, in particular the rhamnosyl residues and glucosyl residues.
  • hexosyl radicals for example allosyl, altrosyl, galactosyl, gulosyl, idosyl, mannosyl and talosyl, may also be used advantageously. It can also be advantageous according to the invention to use pentosyl residues.
  • flavone glycosides from the group ⁇ -glucosyl rutin, ⁇ -glucosyl myrcetin, ⁇ -glucosyl iso-quercitrin, ⁇ -glucosyl iso-quercetin and ⁇ -glucosyl-quercitrin.
  • ⁇ -glucosylrutin is particularly preferred.
  • naringin aurantiin, naringenin-7-rhamnoglucosid
  • hesperidin 3 ', 5,7-trihydroxy-4'-methoxyflavanon-7-rutinoside
  • hesperidoside hesperetin-7-O-rutinoside
  • Rutin (3,3 ', 4', 5,7-pentahydroxyflyvon-3-rutinoside, quercetin-3-rutinoside, sophorin, birutan, rutabion, taurutin, phytomelin, melin), troxerutin (3,5-dihydroxy-3 ', 4', 7-tris (2-hydroxyethoxy) flavon-3- (6-O- (6-deoxy- ⁇ -L-mannopyranosyl) -ß-D-glucopyranoside)), monoxerutin (3.3 ', 4', 5-tetrahydroxy-7- (2-hydroxyethoxy) flavon-3- (6-O- (6-deoxy- ⁇ -L-mannopyranosyl) -ß-D-glucopyranoside)), dihydrorobinetin ( 3,3 ', 4', 5 ', 7-pentahydroxyflavanone), taxifolin (3,3', 4 ', 5,7-pentahydroxyflavanone),
  • the active ingredient (s) from the group of ubiquinones and plastoquinones.
  • Coenzyme Q10 which is characterized by the following structural formula, is particularly advantageous:
  • Creatine and / or creatine derivatives are also preferred active substances for the purposes of the present invention. Creatine is characterized by the following structure:
  • Preferred derivatives are creatine phosphate and creatine sulfate, creatine acetate, creatine ascorbate and the derivatives esterified on the carboxyl group with mono- or polyfunctional alcohols.
  • acyl-carnitine which is selected from the group of substances of the following general structural formula
  • the list of the active substances or combinations of active substances mentioned which can be used in the preparations according to the invention is of course not intended to be limiting.
  • the active ingredients can be used individually or in any combination with one another.
  • selected recipes according to the invention are suitable, which e.g. B. known anti-wrinkle active ingredients such as flavone glycosides (especially ⁇ -glycosylrutin), coenzyme Q10, vitamin E and / or derivatives and the like, particularly advantageous for the prophylaxis and treatment of cosmetic or dermatological skin changes, such as z. B. occur in skin aging. They are also advantageous against the appearance of dry or rough skin.
  • B. known anti-wrinkle active ingredients such as flavone glycosides (especially ⁇ -glycosylrutin), coenzyme Q10, vitamin E and / or derivatives and the like, particularly advantageous for the prophylaxis and treatment of cosmetic or dermatological skin changes, such as z. B. occur in skin aging. They are also advantageous against the appearance of dry or rough skin.
  • Skin aging is e.g. B. caused by endogenous, genetically determined factors. In the epidermis and dermis it occurs due to aging e.g. B. the following structural damage and malfunctions, which may also fall under the term "senile xerosis":
  • Exogenous factors such as UV light and chemical pollutants
  • exogenous factors e.g. B. the following structural damage and functional disorders in the skin, which go beyond the extent and quality of the damage with chronological aging:
  • the present invention relates in particular to products for the care of the naturally aged skin and for the treatment of the consequential damage caused by light aging, in particular the phenomena listed under a) to g).
  • the oil phase of the formulations according to the invention is advantageously selected from the group of polar oils, for example from the group of lecithins and fatty acid triglycerides, especially the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24 , in particular 12 to 18 carbon atoms.
  • the fatty acid triglycerides can for example be advantageously selected from the group of synthetic, semi-synthetic and natural oils, such as. B.
  • cocoglyceride olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, castor oil, wheat germ oil, grape seed oil, safflower oil, evening primrose oil, macadamia nut oil and the like.
  • further advantageous polar oil components can also be selected from the group of esters from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids having a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 C atoms and from the group of esters from aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 C atoms.
  • ester oils can then advantageously be selected from the group octyl palmitate, octyl co-coat, octyl isostearate, octyl dodeceyl myristate, cetearyl isononanoate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl lauron stearate, n-hexyl lauronate, n Isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2-hexyldecyl stearate, 2-octyldodecyl palmitate, stearylheptanoate, oleyl oleate, olerlerucate, erucyl oleate, erucyle
  • the oil phase can advantageously be selected from the group of dialkyl ethers and dialkyl carbonates.
  • oil component (s) from the group isoeikosan, neopentyl glycol diheptanoate, propylene glycol dicaprylate / dicaprate, caprylic / capric / diglyceryl succinate, butylene glycol dicaprylate / dicaprate, C- ⁇ 2 . 13 alkyl lactate, di-C ⁇ 2- ⁇ 3 alkyl tartrate, tri-isostearin, dipentaerythrityl hexacaprylate hexacaprate, propylene glycol monoisostearate, tricaprylin, dimethyl isosorbide. It is particularly advantageous if the oil phase of the formulations according to the invention has a content of C 12-15 alkyl benzoate or consists entirely of this.
  • Advantageous oil components are also e.g. B. butyl octyl salicylate (for example that available under the trade name Hallbrite BHB from CP Hall), hexadecyl benzoate and butyl octyl benzoate and mixtures thereof (Hallstar AB) and / or diethylhexyl naphthalate (Hallbrite TQ).
  • B. butyl octyl salicylate for example that available under the trade name Hallbrite BHB from CP Hall
  • hexadecyl benzoate and butyl octyl benzoate and mixtures thereof Hallstar AB
  • Hallbrite TQ diethylhexyl naphthalate
  • the oil phase can also advantageously also contain non-polar oils, for example those selected from the group of branched and unbranched hydrocarbons and waxes, in particular mineral oil, petroleum jelly (petrolatum), paraffin oil, squalane and squalene, polyolefins, hydrogenated polyisobutenes and isohexa- decane.
  • non-polar oils for example those selected from the group of branched and unbranched hydrocarbons and waxes, in particular mineral oil, petroleum jelly (petrolatum), paraffin oil, squalane and squalene, polyolefins, hydrogenated polyisobutenes and isohexa- decane.
  • polyolefins polydecenes are the preferred substances.
  • the oil phase can advantageously also have a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils.
  • Silicone oils are high-molecular synthetic polymeric compounds in which silicon atoms are linked in a chain and / or network manner via oxygen atoms and the remaining valences of silicon by hydrocarbon residues (mostly methyl, more rarely ethyl, propyl, phenyl groups etc.) are saturated.
  • the silicone oils are systematically considered Designated polyorganosiloxanes.
  • the methyl-substituted polyorganosiloxanes which are the most important compounds of this group in terms of quantity and are characterized by the following structural formula
  • Dimethicone is available in different chain lengths or with different molecular weights.
  • Particularly advantageous polyorganosiloxanes for the purposes of the present invention are, for example, dimethylpolysiloxanes [poly (dimethylsiloxane)], which are available, for example, from Th. Goldschmidt under the trade names Abil 10 to 10,000.
  • phenylmethylpolysiloxanes INCI: phenyl dimethicone, phenyl trimethicone
  • cyclic silicones octamethylcyclotetrasiloxane or decamethylcyclopentasiloxane
  • amino-modified silicones INCI: amodimethicone and silicone.
  • polysiloxane-polyalkylene copolymers (INCI: stearyl dimethicone and cetyl dimethicone) and dialkoxydimethyl polysiloxanes (stearoxy dimethicone and behenoxy stearyl dimethicone), which are available as different Abil-Wax types from Th. Goldschmidt.
  • other silicone oils can also be used advantageously for the purposes of the present invention, for example cetyldimethicone, hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane).
  • z. B. natural waxes of animal and vegetable origin such as beeswax, china wax, bumblebee wax and other insect waxes and shea butter.
  • the preparations according to the invention can advantageously also be in the form of so-called oil-free cosmetic or dermatological emulsions which contain a water phase and at least one UV filter substance which is liquid at room temperature as a further phase.
  • Particularly advantageous UV filter substances which are liquid at room temperature for the purposes of the present invention are homomenthyl salicylate, 2-ethylhexyl-2-cyano-3,3-diphenyl-acrylate, 2-ethylhexyl-2-hydroxybenzoate and esters of cinnamic acid, preferably 4-methoxycinnamic acid (2-ethylhexyl) ester and 4-methoxycinnamic acid isopentyl ester.
  • Homomenthyl salicylate (INCI: Homosalate) is characterized by the following structure:
  • 2-Ethylhexyl-2-cyano-3,3-diphenylacrylate (INCI: Octocrylene) is available from BASF under the name Uvinul ® N 539 and is characterized by the following structure:
  • 2-ethylhexyl-2-hydroxybenzoate (2-ethylhexyl salicylate, octyl salicylate, INCI: octyl salicylate) is available, for example, from Haarmann & Reimer under the trade name Neo Heliopan OS and is characterized by the following structure:
  • 4-methoxycinnamic acid (2-ethylhexyl) ester (2-ethylhexyl-4-methoxycinnamate, INCI: octyl methoxycinnamate) is available, for example, from Hoffmann-La Röche under the trade name Parsol MCX and is characterized by the following structure:
  • Isopentyl 4-methoxycinnamate isopentyl-4-methoxycinnamate, INCI: isoamyl p-methoxycinnamate
  • isoamyl p-methoxycinnamate is available, for example, from Haarmann & Reimer under the trade name Neo Heliopan E 1000 and is characterized by the following structure:
  • the total amount of one or more UV filter substances which are liquid at room temperature in the finished cosmetic or dermatological preparations is advantageously selected from the range from 0.1% by weight to 30% by weight, preferably from 0.5 to 20% by weight , each based on the total weight of the preparations.
  • oil-free emulsions can furthermore, although not necessarily, also contain silicone oils and / or silicone waxes, in particular the abovementioned ones.
  • the water phase of the preparations according to the invention can advantageously contain conventional cosmetic auxiliaries, such as, for example, alcohols, in particular those with a low C number, preferably ethanol and / or isopropanol, diols or polyols with a low C number, and their ethers, preferably propylene glycol, glycerol, ethylene glycol, Ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analog products, polymers, foam stabilizers, electrolytes and in particular one or more thickeners, which one or more can advantageously be selected from the group Silicon dioxide, aluminum silicates, polysaccharides or their derivatives, e.g.
  • conventional cosmetic auxiliaries such as, for example, alcohols, in particular those with a low C number, preferably ethanol and / or isopropanol, diol
  • Moisturizers are substances or mixtures of substances that give cosmetic or dermatological preparations the property of releasing the moisture from the horny layer (also trans- reduce epidermal water loss (called TEWL) and / or have a positive effect on the hydration of the horny layer.
  • TEWL trans- reduce epidermal water loss
  • moisturizers for the purposes of the present invention are, for example, glycerin, lactic acid, pyrrolidone carboxylic acid and urea. Furthermore, it is particularly advantageous to use polymeric moisturizers from the group of water-soluble and / or water-swellable and / or water-gelable polysaccharides. Particularly advantageous are, for example, hyaluronic acid, chitosan and / or a high-fucose polysaccharide, which is filed in the Chemical Abstracts under the registration number 178463-23-5 and z. B. under the name Fucogel®1000 from the company SOLABIA S.A. is available.
  • the cosmetic or dermatological preparations according to the invention can furthermore advantageously, although not necessarily, contain fillers which, for. B. further improve the sensory and cosmetic properties of the formulations and, for example, create or intensify a velvety or silky feeling on the skin.
  • Advantageous fillers for the purposes of the present invention are starch and starch derivatives (such as tapioca starch, distarch phosphate, aluminum or sodium starch, octenyl succinate and the like), pigments which have neither mainly UV filter nor coloring effects (such as e.g. B. boron nitride etc.) and / or Aerosile ® (CAS No. 7631-86-9).
  • Aerosile ® which are available from DEGUSSA AG / Frankfurt, are silicon oxides and are characterized by a small particle size (eg between 5 and 40 nm), the particles being spherical particles of very uniform dimensions. Aerosile ® are macroscopically recognizable as loose, white powders.
  • Aerosil ® - grades are, for example, Aerosil ® OX50, Aerosil ® 130, Aerosil ® 150, Aerosil ® 200, Aerosil ® 300, Aerosil ® 380, Aerosil ® MOX 80 Aerosil ® MOX 170 Aerosil ® COK 84, Aerosil ® R 202, Aerosil ® R 805, Aerosil ® R 812, Aerosil ® R 974, Aerosil ® R976.
  • cosmetic or topical dermatological compositions can be used for the purposes of the present invention, for example as skin protection cream, cleansing milk, day or night cream, etc. It may be possible and advantageous to use the compositions according to the invention as the basis for pharmaceutical formulations.
  • the cosmetic and dermatological preparations according to the invention can contain dyes and / or color pigments, in particular if they are in the form of decorative cosmetics.
  • the dyes and pigments can be selected from the corresponding positive list in the Cosmetics Ordinance or the EC list of cosmetic colorants. In most cases, they are identical to the colorants approved for food.
  • Advantageous color pigments are, for example, titanium dioxide, mica, iron oxides (for example Fe 2 O 3 , Fe 3 O, FeO (OH)) and / or tin oxide.
  • Advantageous dyes are, for example, carmine, Berlin blue, chrome oxide green, ultramarine blue and / or manganese violet. It is particularly advantageous to choose the dyes and / or color pigments from the list below.
  • the Color Index Numbers (CIN) are taken from the Rowe Color Index, 3rd edition, Society of Dyers and Colorists, Bradford, England, 1971.
  • Chlorophyll a and b Copper compounds of chlorophyll ld 75810 green
  • Chromium oxide containing 77289 green
  • Titanium dioxide and its mixtures with mica 77891 white
  • the formulations according to the invention are in the form of products which are used on the face, it is advantageous to choose one or more substances from the following group as the dye: 2,4-dihydroxyazobenzene, 1- (2'-chloro-4'- nitro-1'-phenylazo) -2-hydroxynaphthalene, ceres red, 2- (4-sulfo-1-naphthylazo) -1-naphthol-4-sulfonic acid, calcium salt of 2-hydroxy-1,2'-azonaphthalene-1 '-sulfonic acid, calcium and barium salts of 1- (2-sulfo-4-methyl-1-phenylazo) -2-naphthylcarboxylic acid, calcium salt of 1- (2-sulfo-1-naphthylazo) -2-hydroxynaphthalene-3-carboxylic acid , Aluminum salt of 1- (4-sulfo-1-phenylazo) -2-naphthol-6-sulfonic
  • oil-soluble natural dyes such as. B. paprika extracts, ß-carotene or cochineal.
  • Formulations containing pearlescent pigments are also advantageous for the purposes of the present invention.
  • the types of pearlescent pigments listed below are particularly preferred: 1. Natural pearlescent pigments, such as. B.
  • Pearlescent pigments are based, for example, on powdered pigments or castor oil dispersions of bismuth oxychloride and / or titanium dioxide and bismuth oxychloride and / or titanium dioxide on mica. Particularly advantageous is e.g. B. the gloss pigment listed under CIN 77163.
  • pearlescent pigment types based on mica / metal oxide are also advantageous:
  • pearlescent pigments available from Merck under the trade names Timiron, Colorona or Dichrona.
  • Another preferred pigment is barium sulfate (BaSO 4 ).
  • pearlescent pigments which are advantageous in the sense of the present invention are obtainable in numerous ways known per se.
  • other substrates besides mica can be coated with other metal oxides, such as. B. silica and the like.
  • metal oxides such as. B. silica and the like.
  • Ronaspheren TiO 2 and Fe 2 O 3 coated SiO 2 particles
  • Iron pearlescent pigments which are produced without the use of mica are particularly preferred. Such pigments are e.g. B. available under the trade name Sicopearl copper 1000 from BASF.
  • effect pigments which are available from Flora Tech under the trade name Metasomes Standard / Glitter in various colors (yello, red, green, blue).
  • the glitter particles are present in mixtures with various auxiliaries and dyes (such as, for example, the dyes with the Color Index (Cl) numbers 19140, 77007, 77289, 77491).
  • the dyes and pigments can be present both individually and in a mixture and can be mutually coated, different color effects generally being produced by different coating thicknesses.
  • the total amount of dyes and coloring pigments is advantageously from the range of z. B. 0.1 wt .-% to 30 wt .-%, preferably from 0.5 to 15 wt .-%, in particular the selected from 1.0 to 10 wt .-%, each based on the total weight of the preparations.
  • UV-A or UV-B filter substances are usually incorporated into day creams or makeup products.
  • UV protection substances like antioxidants and, if desired, preservatives, also provide effective protection of the preparations themselves against spoilage.
  • Cosmetic and dermatological preparations which are in the form of a sunscreen are also favorable.
  • Preferred inorganic pigments are metal oxides and / or other metal compounds which are sparingly soluble or insoluble in water, in particular oxides of titanium (TiO 2 ), zinc (ZnO), iron (e.g. Fe;> O 3 ), zirconium (ZrO 2 ), silicon (SiO 2 ), manganese (e.g. MnO), aluminum (AI 2 O 3 ), cerium (e.g. Ce 2 O 3 ), mixed oxides of the corresponding metals and mixtures of such oxides, as well as the sulfate of barium ( BaSO 4 ).
  • zinc oxides can also be used in the form of commercially available oily or aqueous predispersions.
  • Zinc oxide particles and predispersions of zinc oxide particles suitable according to the invention are available under the following trade names from the companies listed:
  • Titanium dioxide pigments according to the invention can be present both in the rutile and anatase crystal modification and, in the sense of the present invention, can advantageously be surface-treated (“coated”), with, for example, a hydrophilic, amphiphilic or hydrophobic character being formed or retained.
  • This surface treatment can consist in that the pigments are provided with a thin hydrophilic and / or hydrophobic inorganic and / or organic layer by methods known per se
  • the various surface coatings can also contain water for the purposes of the present invention.
  • Inorganic surface coatings in the sense of the present invention can consist of aluminum oxide (Al 2 O 3 ), aluminum hydroxide Al (OH) 3 , or aluminum oxide hydrate (also: alumina, CAS no .: 1333-84-2), sodium hexametaphosphate (NaPO 3 ) 6 , sodium metaphosphate (NaPO 3 ) n , silicon dioxide (SiO 2 ) (also: silica, CAS No .: 7631-86-9), or iron oxide (Fe 2 O 3 ).
  • Al 2 O 3 aluminum oxide
  • Al aluminum hydroxide Al
  • Al oxide hydrate also: alumina, CAS no .: 1333-84-2
  • sodium hexametaphosphate (NaPO 3 ) 6 sodium metaphosphate (NaPO 3 ) n
  • silicon dioxide SiO 2
  • silica also: silica, CAS No .: 7631-86-9
  • iron oxide Fe 2 O 3
  • Organic surface coatings in the sense of the present invention can consist of vegetable or animal aluminum stearate, vegetable or animal stearic acid, lauric acid, dimethylpolysiloxane (also: dimethicone), methylpolysiloxane (methicone), simethicone (a mixture of dimethylpolysiloxane with an average chain length of 200 to 350 dimethylsiloxane Units and silica gel) or alginic acid.
  • These organic surface coatings can occur alone, in combination and / or in combination with inorganic coating materials.
  • Coated and uncoated titanium dioxides according to the invention can be used in the form of commercially available oily or aqueous predispersions. Dispersing aids and / or solubilizing agents can advantageously be added to these predispersions.
  • Suitable titanium dioxide particles and predispersions of titanium dioxide particles in the sense of the present invention are available under the following trade names from the listed companies:
  • Z-oxides of the type Z-Cote HP1 and Z-Cote from BASF and NDM and Neutral from Haarmann and Reimer (H&R) are particularly advantageous for the purposes of the present invention.
  • titanium dioxides of the Eusolex T-2000 type from Merck, T 805 from Degussa and MT-100Z and MT-100TV from Tayca are particularly advantageous for use in light protection emulsions.
  • Preparations according to the invention advantageously contain substances which absorb UV radiation in the UV-A and / or UV-B range, the total amount of the filter substances, for. B. 0.1 wt .-% to 30 wt .-%, preferably 0.5 to 20 wt .-%, in particular 1.0 to 15.0 wt .-%, based on the total weight of the preparations to kos -
  • metallic preparations that protect the hair or skin from the entire range of ultraviolet radiation. They can also serve as a sunscreen for the hair or skin.
  • UV-A filter substances for the purposes of the present invention are di-benzoylmethane derivatives, in particular 4- (tert-butyl) -4'-methoxydibenzoylmethane (CAS No. 70356-09-1), which is sold by Givaudan under the brand name Parsol ® 1789 and is sold by Merck under the trade name Eusolex® 9020.
  • di-benzoylmethane derivatives in particular 4- (tert-butyl) -4'-methoxydibenzoylmethane (CAS No. 70356-09-1), which is sold by Givaudan under the brand name Parsol ® 1789 and is sold by Merck under the trade name Eusolex® 9020.
  • UV-A filter substances are phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid
  • salts especially the corresponding sodium, potassium or triethanolammonium salts, in particular the phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid-bis sodium salt
  • 1,4-di (2-oxo-10-sulfo-3-bomylidenemethyl) benzene and its salts especially the corresponding 10-sulfato compounds, especially the corresponding sodium, potassium or triethanolammonium salt
  • benzene-1,4-di (2-oxo-3-bomylidenemethyl-10-sulfonic acid) is also called benzene-1,4-di (2-oxo-3-bomylidenemethyl-10-sulfonic acid) and is characterized by the following structure:
  • Advantageous UV filter substances in the sense of the present invention are also so-called broadband filters, i.e. Filter substances that absorb both UV-A and UV-B radiation.
  • Advantageous broadband filters or UV-B filter substances are, for example, bis-resorcinyltriazine derivatives with the following structure:
  • R 1 , R 2 and R 3 are independently selected from the group of branched and unbranched alkyl groups having 1 to 10 carbon atoms or a single hydrogen atom. Particularly preferred are 2,4-bis - ⁇ [4- (2-ethylhexyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl) -1,3,5-triazine (INCI: Aniso triazine ), which is available under the trade name Tinosorb® S from CIBA-Chemical GmbH.
  • Particularly advantageous preparations within the meaning of the present invention which are distinguished by a high or very high UV-A protection, preferably contain, in addition to the filter substance (s) according to the invention, further UV-A and / or broadband filters, in particular dibenzoylmethane derivatives [ for example the 4- (tert-butyl) - 4'-methoxydibenzoylmethane], phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid and / or its salts, the 1,4-di (2-oxo- 10-sulfo-3-bornylidenemethyl) benzene and / or its salts and / or the 2,4-bis - ⁇ [4- (2-ethylhexyloxy) -2-hydroxy] phenyl ⁇ -6- (4- methoxyphenyl) -1,3,5-triazine, in each case individually or in any combination with one another.
  • UV filter substances which the structural motif
  • UV filter substances for the purposes of the present invention, for example the s-triazine derivatives described in European patent application EP 570838 A1, the chemical structure of which is given by the generic formula
  • R represents a branched or unbranched CrC ⁇ 8 alkyl radical, a C 5 -C 12 cycloalkyl radical, optionally substituted by one or more C 1 -C 4 alkyl groups,
  • X represents an oxygen atom or an NH group, a branched or unbranched CC 18 alkyl radical, a C 5 -C 2 cycloalkyl radical, optionally substituted with one or more CC 4 alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula
  • A represents a branched or unbranched C 1 -C 18 alkyl radical, a C 5 -C 2 cycloalkyl or aryl radical, optionally substituted by one or more CC 4 alkyl groups,
  • R 3 represents a hydrogen atom or a methyl group
  • n represents a number from 1 to 10
  • a branched or unbranched CC 18 alkyl radical a C 5 -C 2 cycloalkyl radical, optionally substituted by one or more CC 4 alkyl groups
  • X represents the NH group
  • a branched or unbranched CC 18 alkyl radical a C 5 -C 12 cycloalkyl radical, optionally substituted by one or more CrC alkyl groups
  • A is a branched or unbranched C 18 -C 18 alkyl radical, a C 5 -C-
  • R 3 represents a hydrogen atom or a methyl group
  • n represents a number from 1 to 10 when X represents an oxygen atom.
  • a particularly preferred UV filter substance in the sense of the present invention is also an asymmetrically substituted s-triazine, the chemical structure of which is represented by the formula
  • dioctylbutylamidotriazon (INCI: dioctylbutamidotriazone) and is available under the trade name UVASORB HEB from Sigma 3V.
  • a symmetrically substituted s-triazine which is 4,4 ', 4 "- (1,3,5-triazine-2,4,6-triyltriimino) -tris-benzoic acid tris (2- ethylhexyl ester), synonym: 2,4,6-tris [anilino- (p-carbo-2'-ethyl-1'-hexyloxy)] - 1,3,5-triazine (INCI: octyl triazone), which is marketed by BASF Aktiengesellschaft under the trade name UVINUL® T 150.
  • European laid-open specification 775 698 also describes bis-resorcinyltriazine derivatives which are to be used preferably, the chemical structure of which is given by the generic formula is reproduced, wherein R ⁇ , R 2 and A ⁇ represent various organic radicals.
  • Also advantageous in the sense of the present invention are the 2,4-bis - ⁇ [4- (3-sulfonato) - 2-hydroxypropyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl) -1, 3,5-triazine sodium salt, the 2,4-bis - ⁇ [4- (3- (2-propyloxy) -2-hydroxypropyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl ) -1, 3,5-triazine, the 2,4-bis - ⁇ [4- (2-ethylhexyloxy) -2-hydroxy] phenyl ⁇ -6- [4- (2-methoxyethyl carboxyl ) -phenylamino] -1, 3,5-triazine, the 2,4-bis - ⁇ [4- (3- (2-propyloxy) -2-hydroxypropyloxy) -2-hydroxy] phenyl ⁇ -6- [4
  • the UV-B and / or broadband filters can be oil-soluble or water-soluble.
  • Advantageous oil-soluble UV-B and / or broadband filter substances are e.g. B .:
  • 3-benzylidene camphor derivatives preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
  • 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
  • esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester
  • esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
  • Advantageous water-soluble UV-B and / or broadband filter substances are e.g. B .:
  • ⁇ sulfonic acid derivatives of 3-benzylidene camphor such as.
  • a further light protection filter substance to be used advantageously according to the invention is ethylhexyl-2-cyano-3,3-diphenylacrylate (octocrylene), which is available from BASF under the name Uvinul ® N 539 and is distinguished by the following structure:
  • the preparations according to the invention advantageously contain the substances which absorb UV radiation in the UV-A and / or UV-B range in a total amount of, for. B. 0.1 wt .-% to 30 wt .-%, preferably 0.5 to 20 wt .-%, in particular 1.0 to 15.0% by weight, based in each case on the total weight of the preparations, in order to provide cosmetic preparations which protect the hair or the skin from the entire range of ultraviolet radiation. They can also serve as a sunscreen for the hair or skin.
  • film formers may also be advantageous to incorporate film formers into the cosmetic or dermatological preparations according to the invention, for example in order to improve the water resistance of the preparations or to increase the UV protection performance (UV-A and / or UV-B boosting).
  • Both water-soluble or dispersible and fat-soluble film formers are suitable, in each case individually or in combination with one another.
  • Advantageous fat-soluble film formers are e.g. B., the film formers from the group of polymers based on polyvinylpyrrolidone (PVP)
  • copolymers of polyvinylpyrrolidone for example the PVP hexadecene copolymer and the PVP eicosen copolymer, which are available under the trade names Antaron V216 and Antaron V220 from GAF Chemicals Cooperation, as well as Tricontayl PVP and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des émulsions cosmétiques ou dermatologiques photoprotectrices caractérisées en ce qu'elles contiennent : a) au moins un dérivé de benzotriazole et b) au moins un type de particules de latex présentant une dimension de particule moyenne comprise entre 100 et 400 nm. L'invention se rapporte en outre à l'utilisation desdites émulsions.
PCT/EP2002/008582 2001-08-04 2002-08-01 Formulations cosmetiques et dermatologiques photoprotectrices contenant des derives de benzotriazole et des particules de latex WO2003013455A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02762421A EP1416912A2 (fr) 2001-08-04 2002-08-01 Formulations cosmetiques et dermatologiques photoprotectrices contenant des derives de benzotriazole et des particules de latex

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10138499.8 2001-08-04
DE10138499A DE10138499A1 (de) 2001-08-04 2001-08-04 Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Benzotriazolderivaten und Latexpartikeln

Publications (2)

Publication Number Publication Date
WO2003013455A2 true WO2003013455A2 (fr) 2003-02-20
WO2003013455A3 WO2003013455A3 (fr) 2003-09-25

Family

ID=7694521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/008582 WO2003013455A2 (fr) 2001-08-04 2002-08-01 Formulations cosmetiques et dermatologiques photoprotectrices contenant des derives de benzotriazole et des particules de latex

Country Status (3)

Country Link
EP (1) EP1416912A2 (fr)
DE (1) DE10138499A1 (fr)
WO (1) WO2003013455A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1537854A1 (fr) * 2003-12-01 2005-06-08 Johnson & Johnson Consumer France SAS Emulsions pulvérisables à haute proportion de lipides
DE102005023635A1 (de) * 2005-05-19 2006-11-23 Beiersdorf Ag Wirkstoffkombinationen aus 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazin und einem oder mehreren Glucosylglyceriden
JP2007126419A (ja) * 2005-11-07 2007-05-24 Iwase Cosfa Kk 紫外線吸収性複合粉体

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918269B1 (fr) 2007-07-06 2016-11-25 Oreal Composition de protection solaire contenant l'association d'un polymere semi-cristallin et de particules de latex creuses.
EP2092930B1 (fr) * 2008-02-22 2017-01-04 Stada Arzneimittel Ag Préparation de protection contre la lumière sous la forme d'émulsions huile/eau ayant un facteur de protection contre la lumière de _> 50
EP2092928A1 (fr) * 2008-02-22 2009-08-26 Stada Arzneimittel Ag Préparation de protection contre la lumière sous la forme d'hydrodispersion ayant un facteur de protection contre la lumière de _> 50
WO2012105060A1 (fr) * 2011-02-04 2012-08-09 L'oreal Pigment composite et son procédé de préparation
EP2872106B2 (fr) 2012-07-13 2023-08-02 L'oreal Pigment composite et son procédé de préparation
WO2014010100A1 (fr) 2012-07-13 2014-01-16 L'oreal Composition cosmétique comprenant des particules composites de protection solaire

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0864316B1 (fr) * 1997-03-10 1999-10-06 L'oreal Compositions cosmétiques photoprotectrices contenant un système filtrant les rayons UV, une dispersion de particules de polymère non-filmogène et une phase grasse
EP1092421A2 (fr) * 1999-10-14 2001-04-18 Rohm And Haas Company Méthode pour préparer des compositions absorbant les radiations UV
EP1281388A1 (fr) * 2001-08-04 2003-02-05 Beiersdorf AG Compositions cosmétiques et dermatologiques ayant un effet protégeant contre la lumière et contenant l'acide 2,2'-(1,4-phénylène)bis-1H-benzimidazole-4,6-disulphonique ou ses sels et des particles de latex
EP1281389A2 (fr) * 2001-08-04 2003-02-05 Beiersdorf AG Preparations cosmetiques et dermatologiques de protection solaire comprenant des particules de latex et des derives de triazine a substitution asymetrique
EP1284129A1 (fr) * 2001-08-17 2003-02-19 Beiersdorf AG Préparations cosmétiques et dermatologiques antisolaires contenant des filtres UV hydrosolubles et de l'acide iminodisuccinique et/ou ses sels

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH032172A (ja) * 1989-02-09 1991-01-08 Yoshitomi Pharmaceut Ind Ltd 新規なベンゾトリアゾール化合物
US5663213A (en) * 1994-02-28 1997-09-02 Rohm And Haas Company Method of improving ultraviolet radiation absorption of a composition
US5945090A (en) * 1997-09-11 1999-08-31 Randall Products International Sunscreen preparation
DE19842786A1 (de) * 1998-09-18 2000-03-23 Beiersdorf Ag Emulgatorfreie feindisperse Systeme vom Typ Öl-in-Wasser und Wasser-in-Öl
DE19842767A1 (de) * 1998-09-18 2000-03-23 Beiersdorf Ag Emulgatorfreie feindisperse Systeme von Typ Öl-in-Wasser und Wasser-in-Öl

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0864316B1 (fr) * 1997-03-10 1999-10-06 L'oreal Compositions cosmétiques photoprotectrices contenant un système filtrant les rayons UV, une dispersion de particules de polymère non-filmogène et une phase grasse
EP1092421A2 (fr) * 1999-10-14 2001-04-18 Rohm And Haas Company Méthode pour préparer des compositions absorbant les radiations UV
US6384104B1 (en) * 1999-10-14 2002-05-07 Rohm And Haas Company Method for preparing ultraviolet radiation-absorbing compositions
EP1281388A1 (fr) * 2001-08-04 2003-02-05 Beiersdorf AG Compositions cosmétiques et dermatologiques ayant un effet protégeant contre la lumière et contenant l'acide 2,2'-(1,4-phénylène)bis-1H-benzimidazole-4,6-disulphonique ou ses sels et des particles de latex
EP1281389A2 (fr) * 2001-08-04 2003-02-05 Beiersdorf AG Preparations cosmetiques et dermatologiques de protection solaire comprenant des particules de latex et des derives de triazine a substitution asymetrique
EP1284129A1 (fr) * 2001-08-17 2003-02-19 Beiersdorf AG Préparations cosmétiques et dermatologiques antisolaires contenant des filtres UV hydrosolubles et de l'acide iminodisuccinique et/ou ses sels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch, Week 199107 Derwent Publications Ltd., London, GB; Class A60, AN 1991-048831 XP002234412 & JP 03 002172 A (YOSHITOMI PHARM IND KK), 8. Januar 1991 (1991-01-08) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1537854A1 (fr) * 2003-12-01 2005-06-08 Johnson & Johnson Consumer France SAS Emulsions pulvérisables à haute proportion de lipides
DE102005023635A1 (de) * 2005-05-19 2006-11-23 Beiersdorf Ag Wirkstoffkombinationen aus 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazin und einem oder mehreren Glucosylglyceriden
JP2007126419A (ja) * 2005-11-07 2007-05-24 Iwase Cosfa Kk 紫外線吸収性複合粉体

Also Published As

Publication number Publication date
WO2003013455A3 (fr) 2003-09-25
DE10138499A1 (de) 2003-02-13
EP1416912A2 (fr) 2004-05-12

Similar Documents

Publication Publication Date Title
EP1371359B1 (fr) Compositions photoprotectrices cosmétiques et dermatologiques contenant des agents absorbant l'UV, des pigments minéraux et des colorants organiques
WO2003039492A1 (fr) Lingettes cosmetiques ou dermatologiques impregnees
EP1434562A1 (fr) Batons cosmetiques et dermatologiques
WO2003053389A1 (fr) Formulations cosmetiques et dermatologiques a effet de protection solaire, contenant des derives de bis-resorcinyltriazine et des derives de benzoxazole
EP1216690B1 (fr) Formulations photoprotectrices cosmétiques et dermatologiques contenant des dérivés de la triazine substitués asymétriquement et des esters citriques tensio-actifs
EP1281390A2 (fr) Utilisation d'une combinaison de charges et de particules de latex pour augmenter le facteur de protection solaire et/ou l'intensité de protection UV-A de compositions cosmétiques ou dermatologiques
EP1474099B1 (fr) Emulsions e/h fluides pulverisables
EP1371358B1 (fr) Compositions photoprotectrices cosmétiques et dermatologiques contenant des agents absorbant l'UV et des polymères organiques synthétiques
EP1371356A2 (fr) Compositions cosmétiques et dermatologiques pour la protection solaire contenant un mélange synergique de filtres UV et de composés sphériques de dioxyde de silicium
EP1416912A2 (fr) Formulations cosmetiques et dermatologiques photoprotectrices contenant des derives de benzotriazole et des particules de latex
WO2002049582A2 (fr) Formulations de protection solaire cosmetiques et dermatologiques contenant des derives benzotriazole et des esters d'acide citrique tensioactifs
EP1371357B1 (fr) Compositions photoprotectrices cosmétiques et dermatologiques contenant des agents absorbant l'UV et des phyllosilicates
EP1281389A2 (fr) Preparations cosmetiques et dermatologiques de protection solaire comprenant des particules de latex et des derives de triazine a substitution asymetrique
EP1281388B1 (fr) Compositions cosmétiques et dermatologiques ayant un effet protégeant contre la lumière et contenant l'acide 2,2'-(1,4-phénylène)bis-1H-benzimidazole-4,6-disulphonique ou ses sels et des particles de latex
WO2002053118A2 (fr) Preparations cosmetiques et dermatologiques de protection solaire comprenant de l'acide phenylen-1,4-bis-(2-benzimidazyl)-3,3'-5,5'-tetrasulfonique et/ou des sels de celui-ci et des esters de saccharose tensio-actifs
EP1216689A2 (fr) Formulations photoprotectrices cosmétiques et dermatologiques contenant des acides phénylène-1,4-bis-(2-benzimidazyl)-3,3'-5,5'-tétrasulfoniques et/ou leurs sels et des esters citriques tensio-actifs
EP1351660A2 (fr) Formulations cosmetiques et dermatologiques photoprotectrices contenant des derives de benzotriazol et des esters de saccharose tensioactifs
EP1365734A2 (fr) Preparations cosmetiques et dermatologiques de protection solaire comprenant des esters de saccharose tensio-actifs
EP1230910A2 (fr) Composition cosmétique et dermatologique photoprotectrice du type émulsion eau-dams-huile et contenant l'éther de cetyle et de stearyle polyoxyéthyléné (20) et des micropigments minéraux hydrophobes
DE20221822U1 (de) Dünnflüssige, sprühbare W/O Emulsionen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): US

Kind code of ref document: A2

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002762421

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002762421

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002762421

Country of ref document: EP